guselkumab vs picankibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT02203032 · Phase 3 · completed
In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.
Next expected readout: December 2026 · NCT05004727 (registry estimate)
Reported efficacy
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)
Result source: NCT02203032
picankibart
Marketed by Innovent Biologics
NCT05645627 · Phase 3 · completed
CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement.
Reported efficacy
Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56): PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons (met)
Result source: NCT06049810
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | picankibart |
|---|---|---|
| PASI 75 | 84.1% vs 6.3%+77.8 vs placeboNCT0232521911 other results
| —Not posted · NCT05645627 |
| PASI 90 | 70% vs 2.4%+67.6 vs placeboNCT0220724410 other results
| 80.3% vs 2%a+78.3 vs placeboNCT05645627 |
| PASI 100 | 50% vs 0%+50 vs placeboNCT029053313 other results
| —Not posted · NCT05645627 |
| sPGA 0/1 | 85.7% vs 7.1%+78.6 vs placeboNCT014835994 other results
| —Not posted · NCT05645627 |
| DLQI, change | -11.2 vs -2.6−8.6 vs placeboNCT0220724410 other results
| —Not posted · NCT05645627 |
PASI 75
- guselkumab
- 84.1% vs 6.3%+77.8 vs placeboNCT02325219
11 other results
- 89.2% vs 6.3% NCT02325219
- 86.3% vs 68.5% NCT02207244
- 92.7% vs 92.8% NCT03090100
- 89.3% vs 91.6% NCT03090100
- 91.2% vs 73.1% NCT02207231
- 78.6% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 75.6% vs 4.8% NCT01483599
- 43.9% vs 4.8% NCT01483599
- 5.1% vs 22.9% NCT03573323
- picankibart
- —Not posted · NCT05645627
PASI 90
- guselkumab
- 70% vs 2.4%+67.6 vs placeboNCT02207244
10 other results
- 73.3% vs 2.9% NCT02207231
- 69.8% vs 0% NCT02325219
- 70.8% vs 0% NCT02325219
- 75.8% vs 0% NCT02905331
- 70% vs 46.8% NCT02207244
- 78.5% vs 79.6% NCT03090100
- 69.1% vs 76.1% NCT03090100
- 73.3% vs 49.7% NCT02207231
- 35.9% vs 58.5% NCT03573323
- 7.9% vs 21% NCT03573323
- picankibart
- 80.3% vs 2%a+78.3 vs placeboNCT05645627
PASI 100
- guselkumab
- 50% vs 0%+50 vs placeboNCT02905331
3 other results
- 24.9% vs 41.3% NCT03573323
- 13.6% vs 29.6% NCT03573323
- 1.4% vs 6.7% NCT03573323
- picankibart
- —Not posted · NCT05645627
sPGA 0/1
- guselkumab
- 85.7% vs 7.1%+78.6 vs placeboNCT01483599
4 other results
- 78.6% vs 7.1% NCT01483599
- 83.3% vs 7.1% NCT01483599
- 61% vs 7.1% NCT01483599
- 34.1% vs 7.1% NCT01483599
- picankibart
- —Not posted · NCT05645627
DLQI, change
- guselkumab
- -11.2 vs -2.6−8.6 vs placeboNCT02207244
10 other results
- -11.2 vs -0.6 NCT02207231
- -8.5 vs -0.8 NCT02325219
- -7 vs -0.4 NCT02325219
- -8.3 vs -0.8 NCT02325219
- -7.5 vs -0.4 NCT02325219
- -10.8 vs -2.3 NCT01483599
- -11.1 vs -2.3 NCT01483599
- -11.4 vs -2.3 NCT01483599
- -10.3 vs -2.3 NCT01483599
- -6.2 vs -2.3 NCT01483599
- picankibart
- —Not posted · NCT05645627
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. guselkumab: 5 of 5 rows · picankibart: 1 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab Rows use multiple source trials | picankibart Rows use multiple source trials |
|---|---|---|
| PASI 90 Response Maintenance responder rate · % of participants Maintenance | 85.2% (n=54) vs 35.7% (n=14) Fumaric Acid Esters @ 56wka,b NCT02951533 · Phase 3 · registry result, not featured evidence | 90.1% vs 51.7% corresponding randomized-withdrawal group @ 56wk200 mg picankibart-maintenancec,a,b NCT06049810 · Phase 3 · sponsor-reported, not registry data show 1 more dose89.3% vs 37.7% corresponding randomized-withdrawal group @ 56wk100 mg picankibart-maintenance NCT06049810 · Phase 3 · sponsor-reported, not registry data |
| Dropout rate | —100 mgd NCT02203032 · Phase 3 show 42 more results3.6%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 1.6%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 9.5% NCT03573323 · Phase 4 · registry result, not featured evidence 13%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 7.6%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 3.1%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 4.8%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | — |
| Discontinued due to AEs | —100 mgd NCT02203032 · Phase 3 show 42 more results1.8%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 0%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 1.6% NCT03573323 · Phase 4 · registry result, not featured evidence 1.3%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 1.9%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 0%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | — |
| Serious AEs | 6.7%100 mgd NCT02203032 · Phase 3 show 42 more results1.6%100 mg NCT02207244 · Phase 3 2.1%100 mg NCT02207244 · Phase 3 14%100 mg NCT02207244 · Phase 3 2.5%100 mg NCT02207231 · Phase 3 2.4%100 mg NCT02207231 · Phase 3 —Guselkumab NCT02905331 · Phase 3 3.2%Guselkumab (Week 0-16) NCT02905331 · Phase 3 1.6%Guselkumab (Week 16-40) NCT02905331 · Phase 3 3.2% NCT03573323 · Phase 4 · registry result, not featured evidence 3.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 5.3%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence 4.7%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 6.3%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 2.2%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 3.5%100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 4.3%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 0%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence 4%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 9.7%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 9.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 5%Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence 0%Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence 5.5%Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 6.2%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence 5%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence | — |
| Most frequent reported AEs | show 37 more results100 mg nasopharyngitis 7.1% (placebo 6.5%) headache 5.1% (placebo 2.8%) upper respiratory tract infection 3.2% (placebo 4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 3.7% (placebo 6.5%) upper respiratory tract infection 2.5% (placebo 4%) arthralgia 1.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 30% (placebo 6.5%) upper respiratory tract infection 23.5% (placebo 4%) arthralgia 9.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 20.1% (placebo 9.8%) upper respiratory tract infection 9.6% (placebo 5.2%) gastroenteritis 3.4% (placebo 1.1%) NCT02207231 · Phase 3 100 mg nasopharyngitis 9.1% (placebo 9.8%) upper respiratory tract infection 7.6% (placebo 5.2%) headache 4.3% (placebo 4%) NCT02207231 · Phase 3 injection site pain 40.3% (placebo 43.8%) injection site coldness 22.6% (placebo 18.8%) injection site pruritus 12.9% (placebo 12.5%) NCT02905331 · Phase 3 injection site pain 18% (placebo 43.8%) injection site coldness 11.5% (placebo 18.8%) viral upper respiratory tract infection 9.8% (placebo 0%) NCT02905331 · Phase 3 upper respiratory tract infection 8.1% nasopharyngitis 5.3% injection site reaction 1.2% NCT03573323 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 16.9% (placebo 3.8%) nasopharyngitis 11.7% (placebo 3.8%) covid-19 6.5% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 24.7% (placebo 3.8%) covid-19 16% (placebo 0%) arthralgia 7.4% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 15.1% (placebo 2.7%) nasopharyngitis 6.7% (placebo 7.1%) covid-19 4.4% (placebo 0.9%) NCT06039189 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 17.6% headache 5.4% back pain 4.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 18.5% hypertension 5.9% arthralgia 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W covid-19 14.7% nasopharyngitis 12.5% psoriasis 7.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 14.1% covid-19 9.3% headache 5.7% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nasopharyngitis 24.3% headache 9% hypertension 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nail psoriasis 22.2% back pain 11.1% covid-19 11.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 15.4% headache 6% back pain 5.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 12.4% covid-19 8.8% psoriasis 8.8% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 50% (placebo 10.9%) eczema 11.3% (placebo 1.6%) injection site erythema 11.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 12.7% (placebo 10.9%) dental caries 3.2% (placebo 1.6%) upper respiratory tract infection 3.2% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 60.3% (placebo 10.9%) arthralgia 14.3% (placebo 0%) influenza 14.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 21.5% (placebo 10.9%) alopecia 3.1% (placebo 0%) arthralgia 3.1% (placebo 0%) NCT02325219 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.7% headache 15% diarrhoea 11.7% NCT02951533 · Phase 3 · registry result, not featured evidence aspartate aminotransferase increased 2.8% tooth infection 2.8% abdominal discomfort 0% NCT02951533 · Phase 3 · registry result, not featured evidence nasopharyngitis 50.9% bronchitis 9.1% alanine aminotransferase increased 5.5% NCT02951533 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 22.1% upper respiratory tract infection 15.5% headache 9% NCT03090100 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 10% (placebo 2.4%) upper respiratory tract infection 7.5% (placebo 2.4%) back pain 5% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 100 mg back pain 4.8% (placebo 0%) headache 4.8% (placebo 2.4%) sinusitis 4.8% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg nasopharyngitis 17.9% (placebo 2.4%) back pain 2.6% (placebo 0%) headache 2.6% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg hypertension 7.1% (placebo 2.4%) fatigue 4.8% (placebo 7.1%) arthralgia 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 13.2% (placebo 2.4%) cough 5.3% (placebo 2.4%) upper respiratory tract infection 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg upper respiratory tract infection 7.3% (placebo 2.4%) cough 4.9% (placebo 2.4%) nasopharyngitis 4.9% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg back pain 2.4% (placebo 0%) nasopharyngitis 2.4% (placebo 2.4%) sinusitis 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg headache 9.8% (placebo 2.4%) nasopharyngitis 9.8% (placebo 2.4%) back pain 2.4% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 15.8% (placebo 2.4%) upper respiratory tract infection 10.5% (placebo 2.4%) arthralgia 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 14.6% (placebo 2.4%) back pain 7.3% (placebo 0%) headache 7.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 13 more results
show 5 more results
show 11 more results
show 14 more results
show 1 more result
show 1 more result
show 1 more result
show 8 more results
+ 97 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)
Result source: NCT05528510
picankibart
Marketed by Innovent Biologics
NCT05377580 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolled 150 patients with moderately to severely active ulcerative colitis and tested several doses of picankibart against placebo. The primary endpoint was clinical remission at Week 12. The sponsor reported remission in 20.0% of patients on 200 mg and 14.0% on 600 mg versus 2.0% on placebo (p<0.05), so the primary endpoint was met; no power calculation or planned enrolment was found in the sources checked.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC) (week 12): Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). (met)
Result source: NCT05377580
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | picankibart |
|---|---|---|
| Clinical remission (induction) | 22.6% vs 7.9%+14.7 vs placeboNCT040334452 other results
| —Not reported |
| Clinical remission (maintenance) | 50% vs 18.9%+31.1 vs placeboNCT040334451 other result
| —Not reported |
| Clinical response (induction) | 61.4% vs 27.6%+33.8 vs placeboNCT040334453 other results
| —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT04033445 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT04033445 | —Not reported |
Clinical remission (induction)
- guselkumab
- 22.6% vs 7.9%+14.7 vs placeboNCT04033445
2 other results
- 21.1% vs 22.2% NCT03662542
- 36.6% vs 22.2% NCT03662542
- picankibart
- —Not reported
Clinical remission (maintenance)
- guselkumab
- 50% vs 18.9%+31.1 vs placeboNCT04033445
1 other result
- 45.2% vs 18.9% NCT04033445
- picankibart
- —Not reported
Clinical response (induction)
- guselkumab
- 61.4% vs 27.6%+33.8 vs placeboNCT04033445
3 other results
- 60.7% vs 27.6% NCT04033445
- 74.6% vs 61.1% NCT03662542
- 83.1% vs 61.1% NCT03662542
- picankibart
- —Not reported
Endoscopic improvement (induction)
- guselkumab
- —Trial running · NCT04033445
- picankibart
- —Not reported
Corticosteroid-free remission (maintenance)
- guselkumab
- —Trial running · NCT04033445
- picankibart
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 4 of 4 rows · picankibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab |
|---|---|
| Dropout rate | 2.8%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0.9%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.6%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3.8%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6.5%200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 5.6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.5%100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.7%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 2.8%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 3.1%Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 200 mg IVa anaemia 7.4% (placebo 10.2%) covid-19 5.6% (placebo 4.6%) abdominal pain 3.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results200 mg IV anaemia 6% (placebo 10.2%) upper respiratory tract infection 4.5% (placebo 0%) colitis ulcerative 3% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC colitis ulcerative 3.8% (placebo 2.8%) headache 3.8% (placebo 7.4%) anaemia 2.5% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV anaemia 5% (placebo 10.2%) covid-19 5% (placebo 4.6%) headache 3% (placebo 7.4%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV covid-19 7.6% (placebo 4.6%) colitis ulcerative 4.1% (placebo 2.8%) nasopharyngitis 2.9% (placebo 1.9%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC covid-19 7% (placebo 4.6%) colitis ulcerative 5.4% (placebo 2.8%) anaemia 4.7% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w to 200 mg SC q4w colitis ulcerative 16.1% (placebo 2.8%) covid-19 6.5% (placebo 4.6%) abdominal pain 3.2% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w covid-19 18.4% (placebo 4.6%) colitis ulcerative 16.8% (placebo 2.8%) pyrexia 6.4% (placebo 4.6%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w colitis ulcerative 13.1% (placebo 2.8%) covid-19 10.1% (placebo 4.6%) arthralgia 8% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w to 200 mg SC q4w covid-19 13% (placebo 4.6%) anaemia 8.7% (placebo 10.2%) colitis ulcerative 8.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w covid-19 14.2% (placebo 4.6%) colitis ulcerative 10.2% (placebo 2.8%) arthralgia 6.1% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 400 mg IV anaemia 8.1% (placebo 10.2%) headache 5.4% (placebo 7.4%) arthralgia 3.6% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.5% upper respiratory tract infection 7% neutropenia 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.6% headache 7.1% colitis ulcerative 5.7% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 1.5% colitis ulcerative 1.5% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 3 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · picankibart's landscape